

Academic Research Monitor

Low-Risk, Low-Volatility, Low-Correlation patterns

Equities

Global

Quantitative

Low-risk patterns are again under our spotlight

The amount of interest in low-risk investing instructs us to look again into the latest academic findings in this space. Where does the performance of low-beta stocks come from; their systemic risk (correlation) or their idiosyncratic risk? How is the performance of low-volatility stocks anyhow related to the profitability anomaly, the distress risk anomaly and the lottery-seeking behaviour? Can hedge funds benefit from the low-risk patterns? We review three recent academic papers and provide insights.

Is Low-Beta due to Low-Correlation or due to Low-Volatility?

A stock's beta is defined as the product of stock volatility and its correlation to the market. One can therefore ask: are the low-beta patterns due to low-correlation or low-volatility (strictly speaking, low-idiosyncratic volatility)? The first paper that we review looks at these dependences and finds that both effects are generally strong. As a result, the low-risk anomaly can be related to leverage constraints (the low-correlation part) as well as to lottery-seeking behaviour (the low-idiosyncratic volatility part).

Connecting Profitability, Distress, Lotteryiness and Volatility

The second paper that we review establishes a link between profitability, distress risk, lottery-seeking behaviour and low-volatility patterns via an expected idiosyncratic skewness channel driven by growth options. Investors expressing preference for positively skewed upside potential specifically driven by corporate growth options should accept lower returns in equilibrium. This justifies the lower returns of higher distress risk, higher lotteryiness, higher idiosyncratic volatility or lower profitability stocks; all these groups of stocks exhibit higher realised idiosyncratic skewness.

Do hedge funds take advantage of the low-risk patterns?

Hedge funds can generally employ leverage and are not evaluated with respect to a benchmark. However, the third paper that we review finds that hedge funds appear (at least on aggregate) to be betting against low-volatility stocks and on high-volatility stocks. This poses a challenge to leverage or benchmarking explanations of the low-risk anomaly. Instead, it promotes a lottery-seeking behaviour as an explanation for the low-risk patterns, given the typical hedge fund fee structure which charges an additional management fee if the performance exceeds some threshold.

David Jessop

Analyst

david.jessop@ubs.com
+44-20-7567 9882

Claire Jones, CFA

Analyst

claire-c.jones@ubs.com
+44-20-7568 1873

Josie Gerken, PhD

Analyst

josephine.gerken@ubs.com
+44-20-7568 3560

Desi Ivanova

Associate Analyst

desi-r.ivanova@ubs.com
+44-20-7568 1754

Paul Winter

Analyst

paul-j.winter@ubs.com
+61-2-9324 2080

Oliver Antrobus, CFA

Analyst

oliver.antrobus@ubs.com
+61-3-9242 6467

Pieter Stoltz

Analyst

pieter.stoltz@ubs.com
+61-2-9324 3779

Josh Holcroft

Analyst

josh.holcroft@ubs.com
+852-2971 7705

Shanle Wu, PhD

Analyst

shanle.wu@ubs.com
+852-2971 7513

Introduction

This issue of our Academic Research Monitor contains the reviews of three recent papers on the low-risk patterns (see Figure 1).¹

The first paper looks at the low-risk anomaly and tries to disentangle the performance into a systematic (i.e. correlation) component and an idiosyncratic risk component. To put this differently, given that the beta of a stock is the product of its volatility and its correlation with the market, the question then becomes: are the low-beta patterns low-correlation patterns or low-volatility (strictly speaking low-idiosyncratic-volatility) patterns?

The second paper draws parallels between four different anomalies that all relate to low-risk patterns: profitability, distress, lotteryiness and volatility. These are shown to be inter-connected via a growth options-driven expected idiosyncratic skewness channel. The growth options-related expected idiosyncratic skewness is shown to command a negative return premium, as investors show preference for positively skewed return profiles coming from future growth options, even if they come with lower average returns. A high-minus-low growth option-driven expected idiosyncratic skewness factor can explain the profitability of the various long-short factors based on profitability, distress, lotteryiness and volatility.

Finally, the third paper explores the ability of low-risk factors to explain the variation of returns of aggregate hedge fund indices. The main finding is that hedge funds are (at least on aggregate) exposed to a low-risk factor, but with the opposite sign than possibly expected. As opposed to taking advantage of the low-risk patterns (given their ability to employ leverage and the lack of benchmarks), the evidence shows that – on aggregate – they bet against low-volatility stocks and favour high-volatility stocks instead.

Figure 1: Papers on Low-Risk Investing

"Betting Against Correlation: Testing Theories of the Low-Risk Effect"

Clifford Asness, Andrea Frazzini, Niels Joachim Gormsen and Lasse Heje Pedersen

[SSRN working paper, January 2017](#)

"Seemingly unrelated stock market anomalies: Profitability, Distress, Lotteryiness and Volatility"

Turan Bali, Luca Del Viva, Neophytos Lambertides and Lenos Trigeorgis

[SSRN working paper, May 2017](#)

"Are Hedge Funds on the Other Side of the Low-Volatility Trade?"

David Blitz

[SSRN working paper, May 2017](#)

Source: UBS.

¹ We have covered low-risk patterns in the ARM a couple of times in the recent past; please see the [February 2016 ARM](#) and the [November 2016 ARM](#). Additionally, please see our recent work on the [dependence of low-risk investing on interest rate changes](#).

"Betting Against Correlation: Testing Theories of the Low-Risk Effect"

by Clifford Asness, Andrea Frazzini, Niels Gormsen & Lasse Pedersen


The fact that stocks with low risk outperform on a risk-adjusted basis the stocks with high risk, contrary to the high-risk/high-return theoretical underpinnings, is a very well established empirical finding that dates back to Black, Jensen and Scholes (1972). The term "low-risk" is broad and encompasses the notions of low systemic risk (i.e. beta) as well as of low volatility (either total or idiosyncratic); see the idiosyncratic volatility anomaly by Ang, Hodrick, Xing and Zhang (2006, 2009) and the betting-against-beta anomaly by Frazzini and Pedersen (2014).

In an effort to rationalise the empirical irregularity of low-risk patterns, academics have suggested a range of potential explanations that can be grouped into two broad categories: (1) if "risk" is proxied by market beta (i.e. systematic risk), then the rational explanation suggests that features of financial intermediation, such as leverage constraints and benchmarking, are driving the low-risk effects; (2) if "risk" is proxied by idiosyncratic volatility, then the low-risk effects can be driven by behavioural biases related to seeking stocks with lottery features. This very recent paper by Clifford Asness, Andrea Frazzini, Niels Gormsen and Lasse Pedersen aims to shed light onto these dependences. Are low-beta effects due to low-volatility or low-correlation with the market? Is it leverage constraints or excess lottery demand that drives low-risk patterns?

In order to empirically study these questions, the authors construct a number of factors that isolate exposure to correlation (hence capturing systematic risk) and exposure to stocks with lottery features (hence capturing idiosyncratic risk). For their empirical analysis, they use US stocks (1963-2015) and stocks from 24 countries (1990-2015). The global (non-US) portfolios are formed as market-capitalisation weighted portfolios of country-specific strategies. The data are collected from CRSP and the XpressFeed Global Database.

Starting from systematic risk, the aim is to decompose the Frazzini and Pedersen (2014) Betting-against-Beta (BAB) strategy into Betting-Against-Correlation (BAC) and Betting-Against-Volatility (BAV) strategies. The methodology that the authors use for the BAC strategy is illustrated in Figure 2 below.

Figure 2: Construction of the Betting-Against-Correlation factor



Source: UBS Quantitative Research. The diagram explains how to construct a Betting-Against-Correlation (BAC) factor using a dependent double-sort methodology.

The procedure entails a dependent double sort, first by historical volatility (estimated using a one-year rolling window of daily returns) into quintiles, and

Beta = Correlation * Volatility

If low-beta outperforms, is it due to the correlation or the volatility?

Leverage constraints

-OR-

Excess lottery demand?

Low-risk from the perspective of systematic risk:

- Betting against beta
- Betting against correlation
- Betting against volatility

then by correlation with the market (estimated using a five-year window of three-day overlapping returns) into low and high. For each volatility quintile a beta-neutralised low minus high correlation portfolio is constructed (this is achieved by leveraging up the low correlation portfolio to an ex-ante beta of one and by leveraging down the high correlation portfolio to an ex-ante beta of one). Each low and high correlation sub-portfolio assumes rank-based weights (so stocks with higher ranks for the high correlation portfolio and lower ranks for the lower correlation portfolio have larger weights). The final BAC portfolio is simply the equal-weighted portfolio of the five BAC sub-portfolios across volatility quintiles. The BAV factor is constructed with the exact same procedure, simply by reversing the order of ranking; first by correlation into quintiles and then by volatility into low and high. It becomes obvious that this above methodology renders the BAC strategy almost independent to volatility and the BAV strategy almost independent to correlation.

Looking at the behavioural aspect of the low-risk patterns and the idiosyncratic risk component of the explanation, the authors construct a number of factors that can capture (partly or solely) the demand for stocks with lottery-like returns. For all these factors, the construction follows the Fama and French (1993) 2x3 size adjusted methodology (the results remain robust to using the methodology outlined in Figure 2), presented in Figure 3 below (the authors use independent sorting for the US and dependent sorting outside the US). Three ranking criteria are used: (1) idiosyncratic volatility (IVOL), estimated using the residuals of a Fama and French (1993) regression framework (US factors for the US universe; Asness and Frazzini (2013) factors for the global universe), (2) the largest maximum return over the past month (MAX) and (3) the ratio of the average of the five largest returns over the past month to the volatility of the stock (SMAX: scaled MAX).

Low-risk from the perspective of idiosyncratic risk and lottery demand:

- Idiosyncratic volatility
- MAX past daily return
- Scaled MAX past daily return

Figure 3: Overview of the Fama and French (1993) factor construction process

Criterion of Interest (e.g. Idiosyncratic Volatility / MAX / Scaled MAX)			
Market Capitalisation	Low	Medium	High
Small	Low / Small (LS)		High / Small (HS)
Large	Low / Large (LL)		High / Large (HL)

$$Factor_t = \frac{1}{2} [LS_t + LL_t] - \frac{1}{2} [HS_t + HL_t]$$

Source: UBS Quantitative Research. The diagram reviews the Fama and French (1993) 2x3 double-sort factor construction methodology that is used in order to construct factors by IVOL, MAX and SMAX (Scaled MAX).

The IVOL anomaly (stocks with low idiosyncratic volatility outperforming stocks with high idiosyncratic volatility) was first studied by Ang et al. (2006, 2009), whereas the LMAX anomaly (stocks with the low maximum daily return over the past month outperform stocks with high maximum daily return over the past month) was first documented by Bali, Cakici and Whitelaw (2011); interestingly, the maximum daily return over the past month has been shown to be related to idiosyncratic skewness by Boyer, Mitton and Vorkink (2009). The SMAX criterion, which is effectively a risk-adjusted form of the MAX criterion, is suggested by the authors of the current paper that we review. The reason why the authors introduce the SMAX measure is because they want to capture lottery demand that is not mechanically related to volatility. The MAX measure can be high either because of a high return realisation or because of higher volatility. A risk-adjusted metric, like SMAX, can therefore identify large moves after controlling for volatility, hence capturing the shape of the return distribution, as the authors argue.

The empirical part of the analysis in the paper consists of a number of experiments aiming to identify whether low-risk patterns are primarily due to leverage constraints, as captured by the BAC strategy, or due to behaviourally-driven lottery

Main finding: both effects (leverage constraints and lottery-seeking demand) drive low-risk patterns

demand, as captured by the SMAX strategy. The actual finding is that both effects play a significant role in the low-risk patterns, and neither of the two subsumes the other. The results are relatively stronger for leverage constraints (and the BAC factor), especially outside the US (where the results of SMAX generally lack strong statistical significance). In the remainder of our review, we summarise some of the most important results that lead to this finding.

Decomposing BAB and LMAX returns

First, the authors show that the BAB and LMAX strategies have no statistically strong alpha, when regressed against their respective components, BAC and BAV or SMAX and total volatility (TV) respectively, both in the US as well as across global equity markets. This effectively means that BAB gets its alpha from betting against high volatility and high correlation with the market and that LMAX gets its alpha from betting against high volatility and high Scaled MAX return. This finding therefore supports that BAC and SMAX factors can – to a certain extent – isolate the systematic and idiosyncratic aspects of low-risk patterns.

Then, the authors look at the alphas of these two strategies, BAC and SMAX, against the Fama and French (1993, 2016) three- and five-factor models. They find strong alphas for both factors in the US. Across global equity markets, it is only the BAC strategy that exhibits statistically significant alphas. The SMAX strategy has statistically strong three-factor alpha, but once the authors control for the profitability (RMW) and the investment (CMA) factors, the statistical significance is lost due to the strong exposure to the profitability factor. The regression analysis generates two more important points: (1) the SMAX strategy is strongly exposed to a short-term reversal strategy; this is quite intuitive, as the SMAX strategy takes a long position on stocks with high returns on their best performing days over the past month; (2) the BAC strategy is strongly and positively exposed to the size factor (so, low correlation stocks across volatility quintiles tend to be small stocks) whereas the BAV strategy is strongly and negatively exposed to the size factor (so, low volatility stocks across correlation quintiles tend to be big stocks).

The economic drivers of returns

Following these results, the authors then look at the economic drivers of BAC and SMAX strategies. To test for leverage constraints, they construct a margin debt variable (amount of margin debt held by customers at NYSE member organisations divided by the market capitalisation of NYSE stocks). To test for irrational lottery demand, they use the investor sentiment index of Baker and Wurgler (2006, 2007). They find that BAB and BAC strategies outperform following periods when leverage constraints are high and during periods when leverage constraints decrease on a contemporaneous basis. Interestingly enough, the profitability of these factors is not related to market sentiment. Conversely, there is some weak evidence that the SMAX, LMAX and IVOL strategies outperform following periods when investor sentiment is high, but neither strategy is related to margin debt. These results are quite insightful, as it becomes clear that leverage constraints only affect systemic risk, whereas investor sentiment only affects idiosyncratic risk.

Turnover implications

The last piece of evidence relates to the turnover of the various strategies and the respective alpha decay if rebalancing takes place less frequently than monthly. The analysis shows that the SMAX, LMAX and IVOL strategies (all of which use information from the last month before portfolio formation) turn over their respective portfolios five to six times more than the BAB, BAC, BAV strategies do. More importantly, the outperformance of the SMAX, LMAX and IVOL strategies is mainly due to high turnover and their alpha falls strongly after the holding month in event time. Conversely, the BAB alpha continues to grow for even up to 12 months after portfolio formation.

"Seemingly unrelated stock market anomalies: Profitability, Distress, Lottery and Volatility"

by Turan Bali, Luca Del Viva, Neophytos Lambertides & Lenos Trigeorgis

Stocks with higher **profitability** outperform their peers. **Distressed** firms underperform their peers. Stocks with **lottery** features underperform their peers. Stocks with low **idiosyncratic volatility** outperform peers. These are four statistically strong empirical observations that seem to go against the **higher-risk-higher-return** paradigm of modern finance theory. Is it possible to reconcile all these market anomalies using one unifying underlying mechanism? The recent paper by Turan Bali, Luca Del Viva, Neophytos Lambertides and Lenos Trigeorgis provides strong empirical evidence that an underlying channel of expected idiosyncratic skewness derived from **growth options** of a firm can explain all these "seemingly unrelated stock market anomalies" as the title suggests.

The main hypothesis of the authors is that *"if investors prefer stocks with embedded real options and have preference for more positive idiosyncratic skewness, then high idiosyncratic skewness offered by firms with such real options might entice investors to accept lower expected returns"*. In other words, **stocks with idiosyncratic upside potential due to corporate growth options should come at a premium** and therefore exhibit **lower returns in equilibrium**. How are the four asset pricing anomalies under consideration related to growth-driven idiosyncratic skewness? High distress risk, high lottery or high idiosyncratic volatility firms are expected by their very nature to involve real options and therefore to exhibit higher idiosyncratic skewness in their distribution of returns. Conversely, high profitability firms are more likely to have realised past growth opportunities and therefore to exhibit lower future idiosyncratic upside potential. These relationships are documented by their authors as explained below in our detailed review.

The rationale: higher upside potential driven by corporate growth options should come at a premium

For their empirical analysis the authors use a dataset that contains all stocks with records in the merged CRSP/Compustat database between 1983 and 2015, **excluding financials and utilities** (12,709 firms in total).

The four criteria associated with the anomalies under consideration are estimated as follows (for further details on the estimation, please consult the actual paper):

- **Profitability:** measured using return-on-equity (ROE), defined as the ratio between operating cash-flows and lagged shareholders' equity.
- **Distress risk:** measured using the negative of Merton's distance to default.
- **Lottery:** measured using the largest daily return over the last month.
- **Idiosyncratic volatility:** measured using the standard deviation of the residuals of a regression of daily stock excess returns on market excess returns and squared market excess returns over the last 5 years of daily observations.

These four characteristics are related to the expected idiosyncratic skewness specifically attributed to corporate growth options. The authors estimate the growth options as well as the historical idiosyncratic skewness as follows:

- **Growth options:** measured as the difference between the firm's current value and the perpetual discounted stream of expected operating cash flows under a no-further-growth policy. Put differently, the growth options measure captures the residual future-oriented growth potential.
- **Idiosyncratic skewness:** measured using the skewness of the residuals of a regression of daily stock excess returns on market excess returns and squared market excess returns over the last 5 years of daily observations.

For the estimation of the expected idiosyncratic skewness of each firm, the authors run a cross-sectional regression at each month-end. The vector of realised idiosyncratic skewness measures of all firms (estimated using the last 5 years of daily data) in the cross-section is regressed against lagged (by 5 years, so that there is no overlap) measures of growth option, profitability, distress risk, lotteryiness, idiosyncratic volatility, idiosyncratic skewness and a good number of other control variables (X), including asset growth, turnover, book-to-price ratio and others:

$$is_{i,t} = \alpha + \beta_{GO} \cdot GO_{i,t-5Y} + \beta_{ROE} \cdot ROE_{i,t-5Y} + \beta_{DR} \cdot DR_{i,t-5Y} + \beta_{LOT} \cdot LOT_{i,t-5Y} + \beta_{iv} \cdot iv_{i,t-5Y} + \beta_{iv} \cdot is_{i,t-5Y} + \sum_j \beta_j \cdot X_{j,i,t-5Y} + \epsilon_{i,t}$$

The result of this regression over the entire sample period (which is equivalent to taking the time-series average of the cross-sectional regression estimates at each month-end) shows a statistically strong relationship between realised idiosyncratic skewness and lagged values of the four ranking criteria of the four anomalies under consideration and of growth options. In particular, higher values of growth options, distress risk, lotteryiness and idiosyncratic volatility are associated with higher future idiosyncratic skewness. Conversely, higher levels of profitability are associated with lower future idiosyncratic skewness (in line with this finding, similar behaviour is documented for the asset growth variable). The results hold both at the univariate and at the multivariate regression setting; they also hold if instead of a cross-sectional regression analysis one conducts a portfolio analysis (forming decile portfolios at each month-end based on any of the ranking criteria and estimating average realised idiosyncratic skewness over the following 5 years).

Having established the cross-sectional relationship between future idiosyncratic skewness and current levels of growth options, profitability, distress risk, lotteryiness and idiosyncratic volatility, the authors then proceed with the estimation of **expected idiosyncratic skewness attributed to growth options**. In particular, after the estimation of the cross-sectional regression above at each month-end, the authors use the latest estimates of growth options for all firms, $GO_{i,t}$, along with the respective slope coefficient $\hat{\beta}_{GO}$ and generate the vector of expected idiosyncratic skewness that is solely due to the impact of growth options:

$$E_t[is_i]_{GO} = \hat{\alpha} + \hat{\beta}_{GO} \cdot GO_{i,t} \quad (1)$$

This is the important variable for the rest of the analysis and it is set against the ranking criteria of the various asset pricing market anomalies under consideration in terms of their ability to forecast (and explain) the cross-section of stock returns. In particular, the authors argue that, as long as growth option-driven expected idiosyncratic skewness is able to capture profitability and investment effects in future returns (in line with Fama and French, 2016), then this variable should assist in explaining stock returns above and beyond standard variables used in the asset pricing literature (size, book-to-price ratio, momentum, profitability etc.).

In cross-sectional regressions of future monthly stocks returns against lagged characteristics (size, book-to-price, 12-month momentum, ROE, asset growth and expected idiosyncratic skewness attributed to growth options), the expected idiosyncratic skewness variable is one of the strongest predictors of returns and subsumes the predictive power of all (but asset growth) variables that are included in the analysis. The slope coefficient is negative, which effectively means that larger expected idiosyncratic skewness is related to lower expected returns. This result is in line with the hypothesis of the authors that investors who express preference for

How is idiosyncratic skewness related to past firm characteristics?

Positive relationship between future realised idiosyncratic skewness and current...

- Growth Options
- Distress Risk
- Lotteryiness
- Idiosyncratic Volatility

Negative relationship between future realised idiosyncratic skewness and current...

- Profitability
- Asset Growth

Estimating growth options-driven expected idiosyncratic skewness

Stocks with higher growth options-driven expected idiosyncratic skewness are priced at a premium

positively skewed upside potential specifically driven by corporate growth options should be willing to accept lower returns in equilibrium. Importantly enough, the earlier analysis showed that stocks with higher realised idiosyncratic skewness are typically stocks with higher distress risk, higher lotteryiness, higher idiosyncratic volatility or lower profitability. The links between the profitability of the respective asset pricing anomalies and the documented effects between future stock returns and expected idiosyncratic skewness should by now have become apparent.

The authors then look at the time-series patterns. They construct a high-minus-low growth option-driven expected idiosyncratic skewness factor and investigate whether this factor can explain the various anomalies in question, in particular high-minus-low profitability, low-minus-high distress risk, low-minus-high lotteryiness, low-minus-high idiosyncratic volatility. Their findings are very strong. These four portfolios have statistically strong average excess returns as well as statistically strong five-factor (against market, size, value, momentum, liquidity factors) alphas. However, when additionally controlling for the skewness factor all alphas fall strongly in magnitude and lose completely any statistical strength. In fact, similarly constructed expected idiosyncratic skewness factors using equation (1) and other variables (as opposed to the growth options variable), for example ROE or idiosyncratic volatility, leave the five-factor alphas unaffected. As the authors put it *"...only future growth options-driven expected idiosyncratic skewness is both consistently priced in stock returns and is able to explain the above anomalous returns."*

In line with these results, the newly introduced skewness factor is shown to completely eliminate the five-factor alpha of various long-short profitability factors suggested in the literature like the one by Fama and French (2016) and the one by Hou, Xue and Zhang (2015). Conversely, these profitability factors cannot explain the returns of the skewness factor, whose alpha remains both economically and statistically strong irrespective of the factor model used to explain its returns.

The investment strategy that takes a long position on the decile with the lowest past year average growth options-driven expected idiosyncratic skewness and a short position on the largest past year average options-driven expected idiosyncratic skewness generates a statistically strong average return between 16% and 18% per annum (equal or market-cap weights respectively) and equally statistically strong alphas based on a number of factor models that the authors test. Interestingly, the performance is primarily driven by the outperformance of the basket of stocks with low options-driven expected idiosyncratic skewness.

As long as market volatility determines the value of corporate growth options, then the expected idiosyncratic skewness effects should become more pronounced during high-volatility regimes. In line with this observation, the authors find the spread between the low and the high decile baskets based on growth options-driven expected idiosyncratic skewness is much stronger (both in terms of economic and statistical significance) in high volatility periods. As a consequence, the negative relationship between growth options-driven expected idiosyncratic skewness and futures stock returns is stronger in high volatility periods.

Overall, we consider the findings of this paper of extreme interest for factor investing allocations. Four seemingly unrelated anomalies are inter-connected via a growth options-driven expected idiosyncratic skewness channel. The growth options-related expected idiosyncratic skewness is shown to command a negative return premium, as investors show preference for positively skewed return profiles coming from future growth options, even if they come with lower average returns.

An idiosyncratic skewness factor to explain a number of asset pricing anomalies

The growth options-driven expected idiosyncratic skewness factor seems to be behind the performance of the profitability factor

"Are Hedge Funds on the Other Side of the Low-Volatility Trade?"

by David Blitz

As already explained quite extensively in the previous reviews, the low-volatility anomaly contradicts the long-standing principle in finance that risk should be compensated for with higher returns and has been generally associated to leverage aversion, short-selling restrictions and benchmark constraints. In his recent paper, David Blitz offers a different perspective on the existence of this anomaly by analysing aggregate hedge fund returns.

One might expect that, since hedge funds do not face the restrictions just mentioned (at least, not at the extent that more traditional investment schemes do), they can potentially benefit from exploiting the low-volatility phenomenon, for example by leveraging up on low-volatility stocks. What the author of this paper deduces, however, is that the behaviour of aggregate hedge fund returns is consistent with taking long positions on high-volatility stocks and short positions on low-volatility stocks. That is, it would seem that the hedge fund industry is on the other side of the low-volatility trade.

The approach the author employs involves regressing a large group of hedge fund index returns on the return differential between low-volatility stocks and high-volatility stocks. The data on hedge fund returns are collected from Thomson Reuters Datastream and contain 20 various Hedge Fund Indices: 7 Hedge Fund Research (HFR) indices and 13 Credit-Suisse (CS) Hedge Fund indices. The former are equally weighted, the latter are weighted by asset size. All returns are in excess of the risk-free rate which is sourced from the Kenneth French website. The multivariate linear model that is used controls for a broad number of variables:

- US equity market excess returns (Mkt);
- Lagged US equity market excess returns (Mkt-1);
- Emerging market returns in excess of US market returns (Em-US);
- The term premium, expressed as the differential return between the Barclays US Treasury index and the risk-free rate (Term);
- The investment grade credit risk premium (IG-Tr);
- The high yield credit risk premium (HY-Tr);
- The return of a time-series multi-asset momentum strategy across commodities, bonds, equities and currencies (TSmom);
- The variance risk premium (VRP);
- The Fama and French (1993) size and value, and the Carhart (1997) momentum factors (SMB, HML and WML).

In addition to the above variables, the author constructs a factor as the return differential between low volatility and high volatility stocks (LV-HV); the volatility is estimated using a rolling window of 36 months. The actual construction of the factor follows the Fama and French (1993) factor construction process (which was schematically presented already in this ARM in Figure 3):

- Classify all stocks in the CRSP database as small or large according to the usual NYSE median market capitalization threshold;
- Construct four value-weighted portfolios; two containing the 30% lowest volatile stocks within each size group and two consisting of the 30% highest volatility stocks within each size group;

Aggregate hedge fund return behaviour points to a consistent preference for high-vol stocks.

Hedge fund data includes 7 HFR indices and 13 CS indices representing various themes.

11 variables are included in the regressions to account for known explanatory factors.

- Subtracting the average (USD) return of the high volatile stock baskets from the average return of the low volatile stock baskets results in the LV-HV factor.

All data is taken at the monthly frequency and the period of analysis covers January 2000 until December 2016.

Once the data has been collated, the 20 hedge fund indices are separately regressed against the LV-HV factor, controlling for the 11 variables listed above; Figure 4 contains the results for the HFR indices. Over the entire sample period, two facts emerge. First, the LV-HV factor consistently belongs to one of the most statistically significant explanatory factors for hedge fund returns. Second, the sign of the coefficient for LV-HV is negative in all but two cases – for the cases where the coefficient is positive, the result is not statistically significant.

Figure 4: Regression Results for HFR hedge fund indices (Jan 2000 – Dec 2016)

	alpha	Mkt	Mkt-1	Em-US	Term	IG-Tr	HY-Tr	TSmom	VRP	SMB	HML	WML	LV-HV	R-sq
HFR Fund Weighted Comp index														
coeff.	0.12%	0.21	0.04	0.11	0.01	0.14	0.02	0.04	0.05	0.01	0.02	0.06	-0.10	92.00%
t-stat.	2.8	13.12	4.18	10.62	0.27	2.58	0.56	3.74	1.27	0.49	1.16	6.62	-7.75	
HFR Fund of Funds Comp index														
coeff.	-0.03%	0.13	0.05	0.09	-0.04	0.20	0.00	0.06	0.06	-0.01	0.01	0.08	-0.08	80.70%
t-stat.	-0.54	6.56	4.81	6.9	-0.77	2.93	0.00	4.02	1.14	-0.59	0.46	7.54	-4.75	
HFR Emerging Markets index														
coeff.	0.14%	0.39	0.08	0.43	0.09	0.06	-0.01	-0.02	0.22	-0.07	0.06	0.08	-0.11	90.80%
t-stat.	1.75	12.48	4.38	20.9	1.17	0.52	-0.24	-0.92	2.71	-2.12	2.13	4.52	-4.21	
HFR Equity Hedge index														
coeff.	0.07%	0.30	0.03	0.14	-0.04	0.21	-0.03	0.01	0.09	0.03	0.06	0.10	-0.14	91.60%
t-stat.	1.13	13.74	2.38	9.4	-0.83	2.72	-0.67	0.40	1.58	1.59	2.80	8.10	-7.75	
HFR Event Driven index														
coeff.	0.18%	0.15	0.06	0.07	0.04	0.07	0.13	0.02	0.15	0.05	0.07	0.04	-0.07	85.10%
t-stat.	3.01	6.94	4.51	4.63	0.73	0.96	3.26	1.28	2.63	2.13	3.14	3.20	-3.75	
HFR Macro index														
coeff.	0.04%	0.07	0.01	0.12	0.02	0.07	-0.08	0.21	-0.08	0.02	0.01	0.02	-0.07	55.70%
t-stat.	0.50	2.43	0.46	5.89	0.31	0.64	-1.34	9.23	-0.98	0.65	0.28	0.89	-2.84	
HFR Relative Value index														
coeff.	0.23%	0.03	0.04	0.04	0.13	0.25	0.13	0.00	0.15	-0.04	0.04	0.04	-0.03	76.50%
t-stat.	4.97	1.59	3.67	3.24	2.94	4.05	3.8	-0.01	3.33	-2.41	2.42	3.68	-1.86	

Source: "Are Hedge Funds on the Other Side of the Low Volatility Trade?" by D. Blitz; Exhibit 1, reproduced with permission. The table reports the results from regressing HFR index returns on LV-HV factor as well as 11 control factors. Sample period: Jan. 2000 – Dec. 2016. Bold figures correspond to statistically significant results at 5%.

The first result is interesting and reveals a new explanatory variable for explaining hedge fund returns. The latter result contradicts the hypothesis that hedge funds systematically exploit the low volatility anomaly simply because they have the means to do so. In fact, what these results imply is that hedge funds, on aggregate, do the exact opposite. That is, take a long bet on high volatility stocks and short low volatility stocks.

Results reveal that LV-HV is a highly significant explanatory factor for describing hedge fund returns.

The evidence shows that the cases where the statistical significance of the LV-HV factor is greatest appear to be associated with hedge funds styles that invest directly in equities.

Regarding the control variables, their significance is generally in accordance with expectations. However, they differ from one fund to the other and depend, largely, on the particular hedge fund strategy. When carrying out the same regressions but excluding LV-HV, the author finds that those insignificant factors

remain insignificant, implying that LH-HV isn't simply creating noise and dissipating the explanatory power of those other variables.

Overall, the general conclusion is that hedge fund index returns are driven by traditional betas, momentum-based factors and a bet against the low-volatility anomaly. This remains true when carrying out the same regressions over the first and second half of the sample period.

Hedge fund index returns are mainly driven by classic betas, momentum-based factors and a bet against low-volatility.

Given the association between the low-volatility anomaly and low-beta anomaly (which we discussed in detail in the review of Bali *et. al* (2017) earlier in the current issue of the ARM), the author replicates the above analysis by replacing LV-HV with a low-minus-high 36-month beta factor (LB-HB). The factor, LB-HB, turns out to be highly correlated with LV-HV at 0.95 over the entire sample period. Therefore, one would expect the results from carrying out the above regressions to be very similar when replacing LV-HV with LB-HB. This isn't necessarily the case, however. What the author finds is that, whilst t-statistics for LB-HB are, on the whole, negative, the statistical significance of this factor and the respective R-squared levels are much lower. Again, all these results point to hedge fund returns being highly exposed to LV-HV.

In addition to the above, further robustness checks are carried out. To dispel any concerns relating to multicollinearity and the fact that both the LV-HV and LB-HB factors might be dominated by the high-risk components, the author repeats the regressions using market-neutral equivalents of the factors; a betting against volatility factor (BAV) and a betting against beta factor (BAB). These are constructed by borrowing cash at the risk-free rate to take a 130% long position in the LV and LB portfolios, then taking a 70% short position in the HV and HB portfolios, investing the remaining 30% at the risk-free rate. Another robustness check is motivated by the relationship between the low volatility anomaly and profitability, as documented in the works by Novy-Marx (2014), Fama and French (2016) and also by Bali *et al.* (2017), which we have already reviewed in the current issue of the ARM. To this end, the same set of regressions are estimated, but this time the LV-HV factor is replaced by profitability (RMW), which is correlated with LV-HV at 0.80. See Figure 5 overleaf for t-statistics relating to these factors.

The last robustness check that the author conducts relates to the possibility that the results are primarily driven by one leg of the LV-HV factor. For that reason, he repeats the analysis using a low-volatility minus medium-volatility factor (LV-MV) and a high-volatility minus medium-volatility factor (HV-MV), either separately or jointly in the regression framework. The findings suggest that hedge funds tend to bet against low volatility and at the same time bet on high volatility (the latter effect appears to be stronger).

In summary, the conclusion remains that hedge funds are predominantly exposed to volatility, but possibly in the opposite way from that initially expected; they bet against low-volatility stocks and in favour of high-volatility stocks. This could potentially pose a challenge to leverage or benchmarking explanations of the low-risk anomaly. Conversely, it could promote a lottery-seeking behaviour as an explanation for the low-risk patterns, given the hedge fund fee structure that charges an additional management fee if the performance exceeds some threshold. Whichever might actually be the case, one of the important findings of the paper is that a low minus high volatility factor appears to explain a significant amount of hedge fund returns, above and beyond conventional factors used in the literature.

Figure 5: T-statistics for LH-HV and related factors (Jan 2000-Dec 2016)

	LV-HV	BAV	LB-HB	BAB	RMW
HFR indices					
HFR Fund Weighted Comp index	-7.75	-7.79	-4.93	-4.92	-4.14
HFR Fund of Funds Comp index	-4.75	-4.98	-2.67	-2.67	-2.56
HFR Event Driven index	-4.21	-4.52	-3.69	-3.89	-1.61
HFR Emerging Markets index	-7.75	-7.53	-5.27	-4.89	-3.35
HFR Equity Hedge index	-3.75	-3.63	-1.53	-1.39	-2.65
HFR Macro index	-2.84	-3.24	-1.41	-1.96	-2.54
HFR Relative Value index	-1.86	-1.56	-1.03	-0.52	0.09
CS indices					
CS Hedge Fund index	-5.23	-5.55	-2.96	-3.15	-3.48
CS Convertible Arbitrage index	-3.06	-2.60	-1.77	-1.23	-0.69
CS Dedicated Short Bias index	0.98	0.87	1.76	1.66	0.22
CS Distressed index	-3.08	-3.10	-1.17	-1.15	-1.57
CS Emerging Markets index	-3.39	-3.81	-3.69	-4.10	-1.09
CS Equity Market Neutral index	-0.77	-0.50	-0.54	-0.29	0.20
CS Event Driven index	-3.97	-3.71	-1.99	-1.61	-1.03
CS Fixed Income Arbitrage index	0.35	0.21	0.96	0.87	0.36
CS Global Macro index	-1.63	-1.87	-0.79	-1.20	-0.33
CS Long/Short Equity index	-5.39	-5.76	-3.47	-3.60	-4.57
CS Managed Futures index	1.09	0.98	1.34	1.05	0.76
CS Multi-Strategy index	-2.52	-2.16	-0.96	-0.47	-0.94
CS Risk Arbitrage index	-2.43	-2.04	-0.78	-0.45	-1.95

Source: "Are Hedge Funds on the Other Side of the Low Volatility Trade?" by D. Blitz; Exhibit 4, reproduced with permission. The table reports the t-statistics from regressing aggregate hedge fund returns on 11 control variables and either LV-HV or one of four related factors. The period under analysis covers January 2000-December 2016. Figures in bold correspond to statistically significant results at 5%.

References

- Ang, A., Hodrick, R. J., Xing, Y., & Zhang, X. (2006). The cross-section of volatility and expected returns. *Journal of Finance*, 61(1), 259-299.
- Ang, A., Hodrick, R. J., Xing, Y., & Zhang, X. (2009). High idiosyncratic volatility and low returns: International and further US evidence. *Journal of Financial Economics*, 91(1), 1-23.
- Asness, C. S., Frazzini, A., Gormsen, N. J., & Pedersen, L. H. (2016). Betting Against Correlation: Testing Theories of the Low-Risk Effect. *Available at SSRN: 2913508*.
- Bali, T. G., Cakici, N., & Whitelaw, R. F. (2011). Maxing out: Stocks as lotteries and the cross-section of expected returns. *Journal of Financial Economics*, 99(2), 427-446.
- Bali, T. G., Del Viva, L., Lambertides, N., & Trigeorgis, L. (2017). Seemingly Unrelated Stock Market Anomalies: Profitability, Distress, Lotteryiness and Volatility. *Available at SSRN: 2974452*.
- Black, F., Jensen, M. C., & Scholes, M. (1972). The Capital Asset Pricing Model: Some Empirical Tests.
- Blitz, D. (2017). Are Hedge Funds on the Other Side of the Low-Volatility Trade? *Available at SSRN: 2898034*.
- Boyer, B., Mitton, T., & Vorkink, K. (2009). Expected idiosyncratic skewness. *Review of Financial Studies*, 23(1), 169-202.
- Carhart, M. (1997) On Persistence in Mutual Fund Performance. *The Journal of Finance*, 52(1), 57-82.
- Fama, E. F., & French, K. R. (1993). Common risk factors in the returns on stocks and bonds. *Journal of Financial Economics*, 33(1), 3-56.
- Fama, E. F., & French, K. R. (2016). Dissecting anomalies with a five-factor model. *Review of Financial Studies*, 29(1), 69-103.
- Frazzini, A., & Pedersen, L. H. (2014). Betting against beta. *Journal of Financial Economics*, 111(1), 1-25.
- Hou, K., Xue, C., & Zhang, L. (2015). Digesting anomalies: An investment approach. *Review of Financial Studies*, 28(3), 650-705.
- Novy-Marx, R. (2014). Understanding defensive equity. National Bureau of Economic Research.

UBS Equity Quantitative Research publications

Monographs, Keys and Q-Series

Academic Research Monitor

Title	Date	Topic	Date
Active vs Passive: What is the Future of Active Management?	Jun-17	Stories about Active Management	Jun-17
The hidden value in fund holdings	Jun-17	UBS UK Quantitative Conference 2017 Highlights	Apr-17
Can social network analysis enhance strategies following trading by corporate insiders?	Jun-17	Recession and Tail Risk?	Mar-17
Using Trend & Carry to time Global Bond Markets	May-17	Where does Volatility Targeting Work?	Jan-17
What you need to know about Japanese equities	Apr-17	ESG Quant Investing	Dec-16
What times the bond market?	Mar-17	Quality, Low-Risk and Momentum Investing	Nov-16
Passive Opportunities for Active Managers	Feb-17	Combining Smart Beta Factors	Sep-16
Active vs Passive: How Will the World of Investing Evolve?	Jan-17	Portfolio Construction and Overfitting	Jul-16
What will demographics mean for growth and stock market returns?	Jan-17	UBS Equity Markets Conference	May-16
How to pick stocks in China's domestic market	Jan-17	European Quantitative Conference 2016 Highlights	Apr-16
Systematic Strategies for Single-Stock Futures	Oct-16	Does Oil matter for Equity Markets?	Mar-16
Irrational asset management	Oct-16	Low Risk Investing	Feb-16
China domestic market – alpha for quantitative investors	Oct-16	Value Investing	Dec-15
Are you already timing styles successfully?	Sep-16	Analyst Forecasts and Measuring Distance	Nov-15
Do low-volatility stocks have interest-rate risk?	Sep-16	UBS Market Microstructure Conference	Oct-15
What does splitting the financials sector change?	Aug-16	Equity Risk Premium Forecasting and Market Timing	Sep-15
Harvesting Yield from Cross-Asset Carry	Aug-16	Behavioural Investing Patterns	Jul-15
When is the stock market likely to correct?	Aug-16	Quality and Size Investing	May-15
Is it easier to be a quant in small cap?	Aug-16	European Quantitative Conference 2015 Highlights	Apr-15
Follow the smart money	Jul-16	Smart Beta, Factors and Style Investing	Feb-15
How can supply chains improve earnings visibility?	Jul-16	Momentum-Investing	Jan-15
Where are the attractive dividend paying stocks?	Mar-16	Investment Strategies & Textual Analysis Signals	Dec-14
Why does increasing volatility matter?	Feb-16	Commodity Risk & Institutional Investing Habits	Nov-14
What crowded positions are bubbling up in equity markets	Feb-16	Index Membership, Investor (in)attention to News & Spurious Correlations	Sep-14
What happened to Value, and when will it return?	Jan-16	Forecasting the Equity Risk Premium	Aug-14
Who benefits from automation?	Nov-15	Implied Cost of Capital & Shorting Premium	Jun-14
The Spectre of Equity-Bond allocation	Nov-15	Trend Following	Mar-14

PAS User Guides

PAS Macros	Feb-16	Reports	Apr-14
Quick Reference Guide	Nov-15	Risk Parity	Feb-13
Risk Parity and Composite Assets	Jan-15	Advanced Analysis	Oct-12
Introduction to the UBS Portfolio Analysis System	Jan-15	Risk Models	Nov-11
Long-Short Analysis	Jan-15	UBS Hybrid Risk Model	Dec-10
Installation	May-14	Quick Portfolio Analysis	Jul-10

R Advice

Tidy Data science with the tidyverse	May-17	Rolling window calculations – which package to use	Oct-16
Bayesian regressions with stan	Mar-17	Getting started with random forests	Sep-16
data.table, the best package in the world?	Mar-17	Optimising in Rs	Aug-16
R and Excel	Dec-16	Speeding up R / Plotting correlation matrices	Jun-16

Team

UK – London

Maylan Cheung	+44-20-7568 4477
Ian Francis	+44-20-7568 1872
Josie Gerken	+44-20-7568 3560
Simon Iley	+44-20-7568 6327
Desi Ivanova	+44-20-7568-1754
David Jessop	+44-20-7567 9882
Claire Jones	+44-20-7568 1873
Manoj Kothari	+44-20-7568 1997
Simon Stoye	+44-20-7568 1876
Christine Vargas	+44-20-7568 2409

Hong Kong

Cathy Fang (Shanghai)	+86-021-3866 8891
Josh Holcroft	+852-2971 7705
Shanle Wu	+852-2971 7513

Australia– Sydney

Oliver Antrobus	+61-3-9242 6467
Luke Brown	+61-2-9324 3620
Pieter Stoltz	+61-2-9324 3779
Paul Winter	+61-2-9324 2080
Nathan Luk	+61-2-9324 2247

Valuation Method and Risk Statement

The articles in this document are based on third party research as disclosed in each piece; however, where this methodology has been applied to a dataset, full responsibility for its application and/or extrapolation is accepted by the analyst.

Our quantitative models rely on reported financial statement information, consensus earnings forecasts and stock prices. Errors in these numbers are sometimes impossible to prevent (as when an item is misstated by a company). Also, the models employ historical data to estimate the efficacy of stock selection strategies and the relationships among strategies, which may change in the future. Additionally, unusual company-specific events could overwhelm the systematic influence of the strategies used to rank and score stocks.

Required Disclosures

This report has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 07 July 2017 04:39 PM GMT.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	46%	30%
Neutral	FSR is between -6% and 6% of the MRA.	38%	28%
Sell	FSR is > 6% below the MRA.	16%	18%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%

Source: UBS. Rating allocations are as of 31 March 2017.

1: Percentage of companies under coverage globally within the 12-month rating category.

2: Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3: Percentage of companies under coverage globally within the Short-Term rating category.

4: Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Limited: David Jessop; Claire Jones, CFA; Josie Gerken, PhD; Desi Ivanova. **UBS Securities Australia Ltd:** Paul Winter; Oliver Antrobus, CFA; Pieter Stoltz. **UBS AG Hong Kong Branch:** Josh Holcroft; Shanle Wu, PhD.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

Global Disclaimer

This document has been prepared by UBS Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo and, in certain instances, UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ("the Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on NEO. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Europe SE. UBS Europe SE is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by

UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Limited, Italy Branch. Where an analyst of UBS Limited, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Limited, Italy Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Mexico:** This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is an affiliate of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please see www.ubs.com/disclosures. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 007/09/2016 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No. 231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg. **New Zealand:** Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this UBS publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CML/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2017. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

